COPZ2

Across TCGA pan-cancer cohorts, COPZ2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated COPZ2 data layer compared with 23 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher COPZ2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated COPZ2 expression acts as an unfavorable survival marker.

CCRCC, LSCC, and GBM are the cancer types where COPZ2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	All	0.502	0.922	.002	72	view →
LSCC	DFS	Tertile	II,III,IV	0.662	0.928	.004	33	view →
GBM	DFS	Quartile	All	0.306	0.551	.006	19	view →
HNSC	DFS	Median	IV	0.569	0.770	.021	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

COPZ2–CCRCC (DFS)

Open the CCRCC breakdown →